Trial Profile

A Randomised controlled tiral to evaluate the efficacy of low molecular-weight heparin on pregnancy outcome of women with previus pregnancy complication

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 05 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enoxaparin sodium (Primary) ; Nadroparin calcium (Primary)
Indications Embolism and thrombosis; Pregnancy complications
Focus Therapeutic Use
Acronyms HAPPY

Most Recent Events

03 Apr 2022 Status changed from recruiting to completed.
08 Feb 2012 The trial was stopped early for futility reasons at the first interim analysis; 21% of nadroparin recipients versus 18% of those in the control group developed pregnancy complications.
30 Jan 2012 Results published in the Blood.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com